Literature DB >> 7109814

[Gastritis - a risk factor in carcinogenesis; epidemiological and morphological findings (author's transl)].

K L Heilmann, C Cuello, W W Hoepker.   

Abstract

A comparison was made between 239 gastric biopsies from persons in Columbia, district of Nariño, not suffering from carcinoma of the stomach and an equal number of biopsies from a german control group matched for age and sex. Carcinoma risk in columbian population is about four fold as high as in german people (150 resp. 40/100,000). 46% of the columbian and 23% of the german group had gastritis of the antrum with atrophic changes; its incidence is independent of age. This type of gastritis is characterized by significantly more areas of necrotic epithelial lesions in the glandular neck region, proliferation and dysplasia of neck cells, as well as by intestinal metaplasia. This active and progredient type of gastritis may be perceived as a preliminary stage of the intestinal ("epidemiological") type of gastric carcinoma. This is the predominant type of carcinoma in Germany as well. Prospective studies are necessary to show, if patients with increased risk of stomach carcinoma can be identified by diagnosing this type of gastritis.

Entities:  

Mesh:

Year:  1982        PMID: 7109814

Source DB:  PubMed          Journal:  Leber Magen Darm        ISSN: 0300-8622


  3 in total

1.  [Where and when does surgery achieve cancer prevention? Precancerous conditions of the stomach].

Authors:  R Häring; G Berger
Journal:  Langenbecks Arch Chir       Date:  1985

2.  Enzyme-linked immunosorbent assay for detection of immunoglobulin A and G antibodies to Campylobacter pylori.

Authors:  H von Wulffen; H J Grote
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

3.  Immunoblot analysis of immune response to Campylobacter pylori and its clinical associations.

Authors:  H von Wulffen; H J Grote; S Gatermann; T Löning; B Berger; C Buhl
Journal:  J Clin Pathol       Date:  1988-06       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.